Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620486 · ClinicalTrials.gov registry record · NA
Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 420
- Enrollment target
NCT04620486: Completed NA study, sponsored by Massachusetts General Hospital.
NCT04620486 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 420 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04620486, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 420 participants
- Enrollment target
Study Summary
The objective is to compare the timeliness of anchor antibiotic administration in the emergency department (ED) after initial dosing with and without a Best Practice Alert in Epic (BPA) implemented to remind physicians to re-order the antibiotic. We hypothesize that post-BPA implementation, physicians will have a higher rate of ordering subsequent doses of antibiotics on-time and with the correct dosages compared to pre-BPA implementation.
Interventions
- OTHER Epic Best Practice Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2022-12-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620486
The ClinicalTrials.gov registry entry for NCT04620486 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epic Best Practice Alert is the first listed.
NCT04620486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04620486 about?
NCT04620486 is a clinical study titled "Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial". The objective is to compare the timeliness of anchor antibiotic administration in the emergency department (ED) after initial dosing with and without a Best Practice Alert in Epic (BPA) implemented to remind physicians to re-order the antibiotic. We hypothesize that post-BPA implementation, physici...
What is the current status of trial NCT04620486?
This trial is currently completed. It is a NA study. The enrollment target is 420 participants. The study started on 2020-10-20. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04620486?
The interventions under investigation include: Epic Best Practice Alert (OTHER).
Who is sponsoring clinical trial NCT04620486?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.